Advertisement

ADVERTISEMENT

bladder cancer

Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
Videos
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
02/25/2021
02/25/2021
Journal of Clinical Pathways
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
02/17/2021
02/17/2021
Journal of Clinical Pathways
The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis
Research Reports
The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis
05/19/2020
Abdalla Aly, PhD
Courtney Johnson, MPH
Yunes Doleh, MPH, PharmD
Viktor Chirikov, MS, PhD
Marc Botteman, MSc
Rahul Shenolikar, MS, PhD
Arif Hussain, MD
Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...
Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...
...
05/19/2020
Journal of Clinical Pathways
Research Reports
Costs of Care for Patients Receiving Chemotherapy for Advanced Bladder Cancer
12/13/2017
Ashish M Kamat, MD, MBBS
Xiting Cao, PhD
Jinghua He, PhD, MPH
Yichen Zhong, MPH
Amishi Y Shah, MD
Kyle Flannery, PharmD, MS
12/13/2017
Journal of Clinical Pathways
Gemcitabine-Based Chemoradiation Effective Bladder Cancer Treatment for Underdeveloped Nations
06/04/2017
JCP Editors
Neoadjuvant gemcitabine-based chemotherapy, followed by gemcitabine-based concomitant chemoradiation, may aid in bladder preservation for patients receiving treatment for muscle-invasive bladder cancer in...
Neoadjuvant gemcitabine-based chemotherapy, followed by gemcitabine-based concomitant chemoradiation, may aid in bladder preservation for patients receiving treatment for muscle-invasive bladder cancer in...
...
06/04/2017
Journal of Clinical Pathways
Real-World Data Shows Metastatic Bladder Cancer Survival Worse Than in Clinical Trials
05/31/2017
JCP Editors
Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research. Current overall survival projections for patients with...
Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research. Current overall survival projections for patients with...
Few...
05/31/2017
Journal of Clinical Pathways
Guideline-Recommended Therapy Underused in Rare Form of Bladder Cancer
05/16/2017
JCP Editors
Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma (MPBC) is often foregone in community cancer centers and academic centers, according to a study presented at the American...
Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma (MPBC) is often foregone in community cancer centers and academic centers, according to a study presented at the American...
...
05/16/2017
Journal of Clinical Pathways
Research in Review
Pembrolizumab Better Than Chemotherapy for Urothelial Cancer
11/14/2016
JCP Editors
An anti-PD-1 therapy significantly improves overall survival (OS) compared with chemotherapy in previously treated patients with advanced bladder (urothelial) cancer, according to a study presented at the Society for...
An anti-PD-1 therapy significantly improves overall survival (OS) compared with chemotherapy in previously treated patients with advanced bladder (urothelial) cancer, according to a study presented at the Society for...
An...
11/14/2016
Journal of Clinical Pathways
Nivolumab Effective for Advanced Bladder Cancer
06/07/2016
JCP Editors
Nivolumab may help to significantly reduce tumor burden in patients with metastatic bladder cancer, regardless of whether their tumors have a biomarker related to the drug’s target, according to clinical trial...
Nivolumab may help to significantly reduce tumor burden in patients with metastatic bladder cancer, regardless of whether their tumors have a biomarker related to the drug’s target, according to clinical trial...
...
06/07/2016
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

June 21 ⁠–⁠ June 22
Psych Congress Regionals
July 18 ⁠–⁠ July 19
July 19 ⁠–⁠ July 20
July 24 ⁠–⁠ July 26
APP Institute Inflammatory Bowel Disease
July 26 ⁠–⁠ July 27
July 27 ⁠–⁠ July 28
July 27 ⁠–⁠ July 28
Psych Congress Regionals
August 8 ⁠–⁠ August 9
August 14 ⁠–⁠ August 17
APP Institute Dermatology
August 16 ⁠–⁠ August 17
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use